Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

2017922 citationsJournal Articlebronze Open Access

Authors

Peter C. Taylor · University of Oxford

Edward Keystone · University of Toronto

Désirée van der Heijde · Leiden University Medical Center

Michael E. Weinblatt · Brigham and Women's Hospital

Liliana Morales · Instituto Oncológico de Córdoba

Jaime Reyes Gonzaga

S. S. Yаkushin · Ryazan Institute of Management and Law

Abstract

In patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab. (Funded by Eli Lilly and Incyte; ClinicalTrials.gov number, NCT01710358 .).

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Autoimmune and Inflammatory Disorders Research Spondyloarthritis Studies and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 376, Issue 7, pp. 652-662

DOI: 10.1056/nejmoa1608345

Field-Weighted Citation Impact: 74.24